Literature DB >> 15625525

Pathology of germ cell tumors of the testis.

Isabell A Sesterhenn1, Charles J Davis.   

Abstract

BACKGROUND: An increasing incidence of testis tumors has been noted over the second half of the 20th century. Congenital malformation of the male genitalia, prenatal risk factors, nonspecific and specific exposures in adulthood, and male infertility have all been associated with the etiology of germ cell tumors.
METHODS: The histologic classification, pathology, and current concepts of testicular germ cell tumors are reviewed.
RESULTS: Germ cell tumors occur at all ages. The tumors are identified as pure form (those of one histologic type) and mixed form (more than one histologic type). Over half of germ cell tumors consist of more than one cell type, requiring appropriate sampling for the correct diagnosis and correlation with the serum tumor markers. Burned-out germ cell tumors may occur in patients with metastatic disease with no gross evidence of a testicular tumor.
CONCLUSIONS: Appropriate management of testis tumors relies on accurate pathology and classification of these tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15625525     DOI: 10.1177/107327480401100605

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  31 in total

1.  Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.

Authors:  Shiyu Tong; Minfeng Chen; Xiongbing Zu; Yuan Li; Wei He; Ye Lei; Wentao Liu; Lin Qi
Journal:  Int Urol Nephrol       Date:  2013-09-01       Impact factor: 2.370

2.  Gastrointestinal bleeding as the first manifestation of a burned-out tumour of the testis.

Authors:  Cecilia Castillo; Gabriel Krygier; Julio Carzoglio; Raúl Cepellini Magariños; Raúl Cepellini Olmos; Juan Jubín; Graciela Sabini
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

3.  Disseminated retroperitoneal choriocarcinoma with open fistula to intestine. "Restitutio ad integrum" with chemotherapy alone.

Authors:  Jaume Capdevila; Pablo Maroto; Sergio Sainz; Humberto Villavicencio
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

Review 4.  Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.

Authors:  Matthew James Reilley; Lance C Pagliaro
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

5.  Intratubular transplantation as a strategy for establishing animal models of testicular germ cell tumours.

Authors:  Yunmin Li; Tatsuo Kido; Jinping Luo; Michiko Fukuda; Ina Dobrinski; Yun-Fai Chris Lau
Journal:  Int J Exp Pathol       Date:  2008-10       Impact factor: 1.925

Review 6.  Adolescent and adult risk factors for testicular cancer.

Authors:  Katherine A McGlynn; Britton Trabert
Journal:  Nat Rev Urol       Date:  2012-04-17       Impact factor: 14.432

Review 7.  Current Concepts of Epigenetics in Testicular Cancer.

Authors:  Alfredo Harb-De la Rosa; Meenakkshy Manoharan; Ahmed Saeed Goolam
Journal:  Indian J Surg Oncol       Date:  2017-01-13

8.  Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving multiple lung metastases that was effectively treated with high-dose chemotherapy.

Authors:  Sang-Cheol Lee; Kyoung Ha Kim; Sung Han Kim; Nam Su Lee; Hee Sook Park; Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2009-12-31       Impact factor: 4.679

9.  Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: a case report.

Authors:  Konstantinos Stamatiou; Panagiotis Papadopoulos; Georgios Perlepes; Nikolaos Galariotis; Michalis Olympitis; Hippocrates Moschouris; Theodora Vasilakaki
Journal:  Cases J       Date:  2009-12-10

Review 10.  MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.

Authors:  Igor Matushansky; Elizabeth Charytonowicz; Joslyn Mills; Sara Siddiqi; Todd Hricik; Carlos Cordon-Cardo
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.